Google Chrome
Safari
Firefox
Edge
Article / Jun 02, 2021
Cleaning Continuous Manufacturing Equipment
Pharmaceutical Technology, 2 Junho 2021
Search
Press Release / Feb 25, 2022
Jean-Luc Herbeaux to become Hovione CEO
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Article / Apr 06, 2026
Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic
Contract Pharma, 6 April 2026
Press Release / Aug 01, 2005
Hovione Group sales grow 8% for fiscal year 2004/05
Hovione announces that the consolidated sales volume for the fiscal year ended 31st March 2005 amounted to US$81.4 million, representing a growth of 8% over the previous year.
Press Release / Sep 20, 2019
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Article / Sep 27, 2021
How the drug services industry found itself prepared for a pandemic
C&EN, 26 September 2021
Sunriser® DPI
High Performance, High-Dose Capsule DPI.
News / Oct 27, 2025
Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing
By David Basile, Vice President, Technical Operations - Americas
Press Release / Jun 07, 2013
Hovione Announces the Appointment of Justin Hughey, PhD to lead Particle Design in the USA
Spray drying
Spray drying has become one of the most successful particle engineering technologies for improving drug bioavailability through the amorphous solid dispersion platform.